Western blot was positive in 77.8% of the animals in the 7 days group, decreasing to a 44.4% in the 90 days group. In the control group, Western blot was positive in 5.5%.

Introducción Varón de 27 años que ingresa en unidad de agudos por estado de agitación psicomotriz y episodio maniforme en probable relación con consumo de cocaína. Objetivo El objetivo de este caso es mostrar al airpiprazol inyectable 9.75 mg como tratamiento eficaz para la agitación psicomotriz y la manía aguda en un paciente consumidor de cocaína Metodología Presentación de caso y revisión de literatura Situacion actual El paciente acude a urgencias por episodio de alteración conductual en via publica. A su llegada presenta marcada agitación psicomotriz. Mantiene un discurso acelerado, taquipsíquico y con descarrilamiento en su discurso. El paciente no presenta antecedentes psiquiátricos. Reconoce un consumo elevado de cocaína desde hace 3 años con aumento en su consumo los últimos meses. Se administra aripiprazol 9.75 mg con diazepam 5 mg intramusculares con mejoría del estado de inquietud. Relata que desde hace una semana se encuentra con sensación de elevada energía junto con ideación delirante de contenido místico y megalomaníaco. Llevaba varios días sin ingerir alimentos, con un consumo diario de cocaína y con disminución importante de las horas de sueño. Se realiza exploración física con pruebas complementarias normales. Durante el ingreso se inicia aripiprazol intramuscular cada 8 horas durante 4 días para más tarde iniciar aripiprazol oral hasta 20 mg día. Los episodios de agitación fueron mitigándose y dándose con menor intensidad y reconducibles verbalmente. Progresivamente se fue organizando su discurso. Respecto al delirio fue distanciándose del contenido delirante pudiendo llegar a realizar crítica tanto de las ideas como del patrón de consumo. conclusión El aripirazol se ha mostrado como un fármaco eficaz para el manejo de episodios maniacos y de sintomatología psicótica. Su formulación intramuscular ha resultado una opción valida para el manejo de episodios de agitación psicomotriz y del tratamiento de sintomaotología maniforme.

IntroductionBrain tumors can be associated with psychiatric symptoms in up to 50% of cases. The most frequent primary is meningioma and the clinic will depend on its location. Since surgical treatment does not always guarantee complete resolution of the condition, concomitant psychopharmacological treatment is usually recommended.ObjectivesTo review about organic mania and its differential diagnosis.MethodsWe carry out a literature review about organic affective disorder accompanied by a clinical description of one patient with organic mania.ResultsA 50-year-old woman admitted due to psychotic symptoms. She had a diagnosis of frontal and parietal meningioma treated with surgical treatment 10 years ago. In this context she had a diagnosis of Organic Affective Disorder and 3 previous psychiatric admissions due to affective or psychotic symptoms. Current episode consisted in dysphoria, magalomanic ideation, delusional ideation of harm and mystical-religious content, high speech pressure and insomnia with little awareness of the disease. Cranial magnetic resonance showed postoperative right frontal changes and stability in parietal meningioma, with no significant differences compared to the previous study. Diagnosis of Organic Affective Disorder is maintained and reintroduced treatment with aripiprazole withdrawaled by the patient weeks before. Because of adverse effects and persistence of the symptoms described, it was changed to olanzapine with good response and tolerability. The behavior was progressively adapted with improvement of the dysphoria and without psychotic symptoms at discharge.ConclusionsAffective symptons due to organic disorders such as brain tumors can be treated surgically and with psychopharmacological treatment.Disclosure of InterestNone Declared

IntroductionThe diagnosis of depression in the elderly patient presents peculiarities that should be taken into account. Studies point out the importance of an adequate screening of suspected cases of depression in older adults by physical therapists and other non-mental health professionals (Ramos Vieira et al., 2014). In this study, we intend to find out which are the most used diagnostic methods in Mental Health research on geriatric patient.ObjectivesTo analyze the diagnostic methods most used in research on the geriatric patient, specifically in articles that analyze the patient with cognitive impairment.MethodsA bibliographic search of all articles analyzing depression in patients with cognitive impairment between 2000 and 2020 was carried out. The diagnostic method of depression in each of them has been collected.ResultsA total of 38 studies were analyzed. The most common diagnostic method continues to be the use of diagnostic criteria (ICD or DSM), which is used in 34.2% of the studies, while the Center for Epidemiologic Studies Depression Scale (CES-D) is the most commonly used test, appearing in 23.7% of the studies. The remaining tests (CIDI, GDS, HAM17, PHQ, SCID, SCL-90, SGDS) do not reach 10% each.Counts% of TotalCumulative %GDS25.3 %5.3 %CES-D923.7 %28.9 %CIDI25.3 %34.2 %Diagnostic criteria1334.2 %68.4 %EURO-D12.6 %71.1 %PHQ25.3 %76.3 %GMS-AGECTA25.3 %81.6 %HAM-1712.6 %84.2 %Others615.8 %100 %ConclusionsThe diagnosis of depression continues to be made primarily using diagnostic criteria. It is striking that the most commonly used test is the CES-D, given that the Geriatric Depression Scale (GDS) is usually the most popular scale for screening for late-life depression (Gana et al., 2017), which may be due to the fact that the studies analyzed have a more research than clinical purpose.ReferencesGana, K., Bailly, N., Broc, G., Cazauvieilh, C., & Boudouda, N. E. (2017). The Geriatric Depression Scale: does it measure depressive mood, depressive affect, or both?. International journal of geriatric psychiatry, 32(10), 1150–1157.Vieira, E. R., Brown, E., & Raue, P. (2014). Depression in older adults: screening and referral. Journal of geriatric physical therapy (2001), 37(1), 24–30.Disclosure of InterestNone Declared

IntroductionWe often find it challenging to manage hyperactivity, low frustration tolerance and angry outbursts in patients with ASD and comorbid ADHD. Fewer drugs are approved for these disorders and these patients are more likely to develop adverse effects.ObjectivesThe aim of this case is to show how the combination of lisdexamfetamine together with guanfacine has very positive effects on anger outbursts and boundary heteroaggressiveness in patients with ASD and ADHD.MethodsCase report and literature reviewResultsThis is a 14-year-old minor admitted to the psychiatric unit after physical aggression against his family due to anger after removal of video games, requiring police intervention. He has been diagnosed since he was 11 years old with ADHD and Autism Spectrum Disorder. He was being treated with methylphenidate 54 mg and aripiprazole 10 mg. Since the beginning of the admission, the following pharmacological adjustment has been made: Methylphenidate is substituted by lisdexamfetamine up to 50 mg per day. Guanfacine has been started up to 4 mg per day and the dose of aripiprazole has been maintained. The patient had no adverse effects with adequate tolerance without sedation, hyporexia or hypotension. With this adjustment, improvement was found in the levels of restlessness and hyperactivity. The patient expressed a subjective improvement in the levels of restlessness and with a notable improvement in attention in the hospital classroom. An improvement in emotional regulation was also observed, with more tolerance to the imposition of limits, without an explosion of anger in the face of any rule during admissionConclusionsThe management of hyperactivity and episodes of low frustration tolerance in patients with ASD and ADHD is complex. Many studies point out the time-limited use of some antipsychotics such as risperidone or aripiprazole. This work aims to show guanfacine in combination with lisdexamfetamine as an excellent combination for the management of agitation and rage explosion in these patients. In addition, the profile of adverse effects at metabolic level is much better than that of atypical antipsychotics.Reference-Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Lawrence Scahill et al. Am J Psychiatry. 2015 Dec.Disclosure of InterestNone Declared